GAD-6: A Modified Anxiety Screening Tool
The GAD-6 is not a standardized or widely recognized clinical tool—you are likely asking about the GAD-7 (7-item Generalized Anxiety Disorder scale), which is the validated screening instrument recommended in clinical guidelines.
What is the GAD-7?
The GAD-7 is a 7-item self-report questionnaire designed to screen for generalized anxiety disorder in primary care and other clinical settings 1, 2. It assesses how often patients have been bothered by anxiety symptoms over the past two weeks.
The Seven Items:
- Feeling nervous, anxious, or on edge
- Not being able to stop or control worrying
- Worrying too much about different things
- Having trouble relaxing
- Being so restless that it is hard to sit still
- Becoming easily annoyed or irritable
- Feeling afraid, as if something awful might happen
Each item is scored on a 4-point scale:
- 0 = Not at all
- 1 = Several days
- 2 = More than half the days
- 3 = Nearly every day
Scoring and Interpretation
Total scores range from 0 to 21, calculated by summing all seven items 1, 2.
Score Interpretation:
- ≥5 points: Mild anxiety
- ≥10 points: Moderate anxiety
- ≥15 points: Severe anxiety 1
Screening Cutoffs:
- ≥8-9 points: Positive screen requiring further evaluation 2
- A cutoff of 9 points has higher positive likelihood ratio (LR+ = 4.3) compared to 8 points, with similar negative likelihood ratio (LR- = 0.13) 2
Clinical Management Based on Scores
Mild Anxiety (5-9 points):
- Monitor symptoms
- Provide psychoeducation about anxiety
- Consider lifestyle modifications (reduce caffeine, improve sleep hygiene, exercise)
- Reassess in 2-4 weeks
Moderate Anxiety (10-14 points):
- Conduct further diagnostic assessment to determine if criteria for GAD or other anxiety disorder are met 1
- Rule out medical causes (hyperthyroidism, substance use, medication side effects)
- Initiate treatment with psychotherapy (CBT preferred) and/or pharmacotherapy 1
- Refer to mental health specialist if symptoms persist or worsen
Severe Anxiety (≥15 points):
- Immediate further diagnostic evaluation required 1
- Assess for suicidality and risk of harm to self or others—if present, refer for emergency psychiatric evaluation 1
- Strongly consider referral to psychiatrist or psychologist 1
- Initiate combined pharmacologic and psychotherapeutic interventions
- Close follow-up (within 1-2 weeks)
Important Clinical Caveats
The GAD-7 is a screening tool, not a diagnostic instrument—positive screens require comprehensive clinical assessment to confirm diagnosis 1.
Ultra-short version: The GAD-2 (first two items only) can be used for rapid screening. A score ≥3 has LR+ of 5.1 and should prompt full GAD-7 administration 2.
Comorbidity alert: 50-60% of patients with depressive disorders have comorbid anxiety, so screen for both conditions 1. The guideline recommends starting with PHQ-9 for depression screening, then using GAD-7 for anxiety assessment 1.
Medical causes must be excluded: Treat underlying conditions like uncontrolled pain, fatigue, or substance-induced symptoms before attributing symptoms solely to anxiety disorder 1.
Note on GAD-6
Recent research has explored a modified 6-item version (GAD-6) by removing item #7 ("Feeling afraid, as if something awful might happen") and merging response categories, showing improved psychometric properties in specific populations like French adolescents 3 and Malaysian adults 4. However, this is not yet a standardized clinical tool and should not be used in routine practice—stick with the validated GAD-7 1, 2.